Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

Literature DB >> 32531754

Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?

Clara Aguirre¹, Virginia Meca-Lallana², Ana Barrios-Blandino³, Beatriz Del Río², Jose Vivancos⁴.

Abstract

The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS) treatment, acts blocking α4-integrin. We report a MS patient treated with natalizumab who develops COVID-19, with excellent recovery and repeated negative results in 5 consecutive microbiological studies. We postulate this may be due to the blockade of integrins induced by natalizumab.

Entities: Chemical Disease Gene Species

Keywords: COVID-19; Integrins; Multiple Sclerosis; Natalizumab; SARS-CoV-2

Year: 2020 PMID： 32531754 DOI： 10.1016/j.msard.2020.102250

Source DB: PubMed Journal: Mult Scler Relat Disord ISSN： 2211-0348 Impact factor: 4.339

14 in total

1. Integrins as Therapeutic Targets for SARS-CoV-2.

Authors: Timothy E Gressett; Danielle Nader; Juan Pablo Robles; Tione Buranda; Steven W Kerrigan; Gregory Bix
Journal: Front Cell Infect Microbiol Date: 2022-04-29 Impact factor: 6.073

Review 2. Immunology of COVID-19 and disease-modifying therapies: The good, the bad and the unknown.

Authors: Tobias Zrzavy; Isabella Wimmer; Paulus S Rommer; Thomas Berger
Journal: Eur J Neurol Date: 2020-11-08 Impact factor: 6.288

Review 3. COVID-19 illness and autoimmune diseases: recent insights.

Authors: Juan Li; Hong-Hui Liu; Xiao-Dong Yin; Cheng-Cheng Li; Jing Wang
Journal: Inflamm Res Date: 2021-02-28 Impact factor: 4.575

4. The Spike Glycoprotein of SARS-CoV-2 Binds to β1 Integrins Expressed on the Surface of Lung Epithelial Cells.

Authors: Eun Jeong Park; Phyoe Kyawe Myint; Michael Gyasi Appiah; Samuel Darkwah; Siqingaowa Caidengbate; Atsushi Ito; Eri Matsuo; Eiji Kawamoto; Arong Gaowa; Motomu Shimaoka
Journal: Viruses Date: 2021-04-09 Impact factor: 5.048

Review 5. Multiple sclerosis and COVID-19: The Swedish experience.

Authors: Anne-Marie Landtblom; Shala G Berntsson; Inger Boström; Ellen Iacobaeus
Journal: Acta Neurol Scand Date: 2021-05-24 Impact factor: 3.915

6. Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection.

Authors: Doriana Landi; Gaia Cola; Vittorio Mantero; Roberto Balgera; Lucia Moiola; Agostino Nozzolillo; Vincenzo Dattola; Leonardo Sinisi; Roberta Fantozzi; Sonia Di Lemme; Diego Centonze; Giorgia Mataluni; Carolina Gabri Nicoletti; Girolama Alessandra Marfia
Journal: Mult Scler Relat Disord Date: 2021-10-24 Impact factor: 4.339

7. The Integrin Binding Peptide, ATN-161, as a Novel Therapy for SARS-CoV-2 Infection.

Authors: Brandon J Beddingfield; Naoki Iwanaga; Prem P Chapagain; Wenshu Zheng; Chad J Roy; Tony Y Hu; Jay K Kolls; Gregory J Bix
Journal: JACC Basic Transl Sci Date: 2020-10-16

Review 8. Multiple Sclerosis Disease-Modifying Therapy and the COVID-19 Pandemic: Implications on the Risk of Infection and Future Vaccination.

Authors: Crystal Zheng; Indrani Kar; Claire Kaori Chen; Crystal Sau; Sophia Woodson; Alessandro Serra; Hesham Abboud
Journal: CNS Drugs Date: 2020-09 Impact factor: 5.749

9. Mild COVID-19 infection in a group of teriflunomide-treated patients with multiple sclerosis.

Authors: Vittorio Mantero; Damiano Baroncini; Roberto Balgera; Clara Guaschino; Paola Basilico; Pietro Annovazzi; Mauro Zaffaroni; Andrea Salmaggi; Christian Cordano
Journal: J Neurol Date: 2020-08-31 Impact factor: 4.849

10. A New England COVID-19 Registry of Patients With CNS Demyelinating Disease: A Pilot Analysis.

Authors: Kelli M Money; Ashmanie Mahatoo; Soleil Samaan; Pria Anand; Ursela Baber; Mary Bailey; Rohit Bakshi; Andrew Bouley; Aaron Bower; Jonathan Cahill; Maria Houtchens; Joshua Katz; Ellen Lathi; Elle Levit; Erin E Longbrake; Matthew McAdams; Salvatore Napoli; Pooja Raibagkar; Peter Wade; Jacob A Sloane
Journal: Neurol Neuroimmunol Neuroinflamm Date: 2021-08-02